Del Carmen Jeffrey 4

4 · CATALYST PHARMACEUTICALS, INC. · Filed Nov 24, 2025

Form 4

Period: 2025-11-20

Chief Commercial Officer

Transactions

Award
Options to purchase common stock
2025-11-20+106,873→ 1,037,881 total
Exercise: $22.77Exp: 2032-11-20→ Common Stock (106,873 underlying)
Exercise/Conversion
Common Stock, par value $0.001 per share
2025-11-21+5,603→ 5,603 total
Award
Restricted Stock Units
2025-11-20+32,257→ 1,070,138 total
→ Common Stock (32,257 underlying)
Tax Payment
Common Stock, par value $0.001 per share
2025-11-21−1,641→ 3,962 total
Exercise/Conversion
Restricted Stock Units
2025-11-21−5,603→ 1,064,535 total
→ Common Stock (5,603 underlying)

Footnotes (6)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
[F2]Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
[F3]Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.
[F4]Shares of common stock will be delivered to the Reporting Person upon vesting.
[F5]Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
[F6]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.

Documents

1 file